Novel Therapies in BCMA|exposed Relapsed/Refractory Multiple ...

Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple ...

In this review, we discuss the different mechanisms of resistance to anti-BCMA therapies, effective retreatment with anti-BCMA-targeted therapies in MM,

Novel Treatments for Patients With Relapsed/Refractory Multiple ...

Belantamab mafodotin (Blenrep) was approved in August 2020 and is a monoclonal antibody that binds to the surface protein B-cell maturation antigen (BCMA) on ...

Novel BCMA-targeting therapies to treat TCE relapsed/refractory ...

ASCO 2024 | Novel BCMA-targeting therapies to treat TCE relapsed/refractory multiple myeloma ... Xavier Leleu, MD, PhD, Poitiers University ...

Anti-BCMA novel therapies for multiple myeloma - PMC

However, MM patients still do relapse and MM is considered an incurable disease. ... Therefore, novel therapies, especially for relapsed/ ...

Clinical Trial Utilizes Novel CAR Target for Relapsed/Refractory ...

Most multiple myeloma patients with relapsed/refractory disease will undergo CAR T-cell therapy targeting B-cell maturation antigen (BCMA), ...

Novel BCMA-targeting therapies to treat TCE relapsed ... - YouTube

Novel BCMA-targeting therapies to treat TCE relapsed/refractory multiple myeloma ; Kenneth C. Anderson - Multiple myeloma cured in 2030: what are ...

The Gaining Momentum of BCMA-Directed Therapies for Relapsed ...

Among novel therapeutic modalities, B-cell maturation antigen (BCMA)-directed immunotherapies, including chimeric antigen receptor (CAR) T-cell ...

The Anti-BCMA Therapy-refractory Patient - touchONCOLOGY

Anti-BCMA CAR. BCMA. Cytokine release from immune response. Page 3. Novel Therapies in BCMA-exposed Relapsed/Refractory Multiple Myeloma. 61.

(PDF) Novel Therapies in BCMA-exposed Relapsed/Refractory ...

The development of chimeric antigen receptor T-cell (CAR-T) therapy has shown promising results utilizing several target antigens; of note, B- ...

Salvage therapies including retreatment with BCMA-directed ...

For patients with relapsed/refractory multiple myeloma with a relapse after B-cell maturation antigen (BCMA)–directed chimeric antigen receptor T-cell therapy ( ...

Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed ...

Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy ...

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory ...

Treatment of relapsed and/or refractory multiple myeloma (RRMM) utilizing the novel therapeutic target of the B-cell maturation antigen ...

Relapsed/Refractory Multiple Myeloma: Sequencing BCMA ...

Shared perspective on available novel therapies in relapsed/refractory multiple myeloma and how best to sequence these agents.

Current Novel Targeted Therapeutic Strategies in Multiple Myeloma

Cevostamab is a FcRH5×CD3 bispecific antibody under investigation as a potential therapy for RRMM, particularly in the setting of relapse after BCMA-directed ...

Sequencing anti-BCMA therapies in myeloma - ASH Publications

Blood (2023) 141 (3): 211–212. ... Several therapeutic agents target the B-cell maturation antigen (BCMA) in multiple myeloma (MM). In this issue ...

Individualized Strategies for Relapsed/Refractory Multiple Myeloma

Even with aggressive initial therapy, most patients experience relapse, and the 5-year survival rate is just 56%. The recent boon of novel ...

Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory ...

Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has ...

Serial treatment of relapsed/refractory multiple myeloma with ...

Several novel BCMA-specific therapies, including antibody-drug conjugates, chimeric antigen receptor (CAR) T cells, and bispecific antibodies, ...

Treatment of Relapsed or Refractory Multiple Myeloma With BCMA ...

Despite advances in treatment, including the induction of durable remissions, the inevitable relapse necessitates the exploration of novel therapeutic avenues.

Novel Therapies Surge Forward in Relapsed/Refractory Multiple ...

Martin: On clinicaltrials.gov, there are over 40 ongoing clinical trials of BCMA-targeted therapeutics. The majority of these studies are [ ...